Clinical Trial Update: A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating eltrombopag's ability to induce a sustained off-treatment response in subjects with immune thrombocytopenic purpura. Results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenic Purpura

Drugs mentioned

• Eltrombopag (eltrombopag)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Immune Thrombocytopenic Purpura (ITP) | Phase 2 | Status: COMPLETED | Results posted: 2023-12-27